SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Accounting Policies) (Details) $ / shares in Units, $ in Thousands			3 Months Ended	12 Months Ended
		Jan. 27, 2014 $ / shares	Dec. 31, 2015 USD ($) $ / shares	Dec. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2014 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, par value (in usd per share) | $ / shares	[1]	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Common stock reverse stock split, conversion ratio		0.0833
Other current assets			$ 537	$ 537	$ 385
Prepaid expense			200	200
Unbilled receivables			100	100
Other receivables			200	200
Impairment of intangibles				$ 6,200
Impairment of goodwill			6,900
Equity awards, contractual term				10 years
Deferred revenue			217	$ 217	298
Foreign currency translation adjustment				$ (330)	$ (50)
Options, warrants and conversion rights, common stock callable and antidilutive (in shares) | shares				9,963,886	6,613,572
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity awards, vesting period				1 year
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity awards, vesting period				3 years
Familion | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated economic life				7 years
Familion | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated economic life				15 years
Pharmacogenomic services
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred revenue			$ 100	$ 100	$ 300

[1] The common stock shares and additional paid-in capital for all periods presented reflect the one-for-twelve reverse stock split which took effect on January 27, 2014.